Connect with us

Technology

Whirlpool Announces Pricing of Cash Tender Offer

Published

on

BENTON HARBOR, Mich., June 15, 2026 /PRNewswire/ — Whirlpool Corporation (NYSE: WHR) (“Whirlpool” or the “Company”) announced today the pricing of its previously announced (i) tender offer (the “Tender Offer”) to purchase for cash any and all of the outstanding 1.250% Notes due 2026 (the “2026 Notes”) and 1.100% Notes due 2027 (the “2027 Notes” and together with the 2026 Notes, the “Notes”) of Whirlpool Finance Luxembourg S.à r.l., a private limited liability company (société à responsabilité limitée) organized under the laws of the Grand Duchy of Luxembourg (the “Issuer”) and wholly owned subsidiary of the Company, and (ii) solicitation of consents from holders of the 2027 Notes (the “Consent Solicitation”) to a proposed amendment (the “Proposed Amendment”) to the indenture governing the 2027 Notes, dated as of November 2, 2016 (the “Indenture”).

The following table details the Reference Yield, Fixed Spread, Tender Offer Consideration, Early Tender Premium and Total Consideration (each as defined in the Offer to Purchase and Consent Solicitation Statement (as defined below)) for each series of Notes.

Title of Notes

ISIN/Common
Code(1)

Reference
Yield

Fixed
Spread

Tender Offer
Consideration(2)(3)

Early Tender
Premium(2)

Total
Consideration
(2) (3)(4)(5)

1.250% Notes
due 2026

XS1514149159 /

151414915

2.345 %

50 bps

€944.09

€50.00

€994.09

1.100% Notes
due 2027

XS1716616179 /
171661617

2.534 %

50 bps

€923.94

€50.00

€973.94

(1)

No representation is made as to the correctness or accuracy of the ISINs or Common Codes listed in this release and the Offer to Purchase and Consent Solicitation Statement or printed on the Notes. They are provided solely for the convenience of holders of the Notes.

(2)

Per €1,000 principal amount of Notes tendered and accepted for purchase.

(3)

Excludes accrued and unpaid interest from the last date on which interest has been paid to, but excluding, the Early Settlement Date or the Final Settlement Date (each as defined below), as applicable, that will be paid on the Notes accepted for purchase.

(4)

Includes the Early Tender Premium.

(5)

The Total Consideration in respect of each series of Notes was calculated at or around 4:00 p.m., Central European time (10:00 a.m., New York City time), today in accordance with standard market practice, as described in the Offer to Purchase and Consent Solicitation Statement.

The Company has elected to exercise its right to make payment for Notes that were validly tendered at or prior to 5:00 p.m., Central European time (11:00 a.m., New York City time), on June 12, 2026 (the “Early Tender Expiration”) and that are accepted for purchase on or about June 18, 2026 (the “Early Settlement Date”). Each holder of the Notes (each, a “Holder” and collectively, the “Holders”) who validly tendered and did not validly withdraw its Notes at or prior to the Early Tender Expiration and whose Notes are accepted for purchase will be entitled to receive the Total Consideration (as set forth in the table above), which includes the Early Tender Premium (as set forth in the table above), together with accrued and unpaid interest, if any, from and including the last date on which interest has been paid to, but excluding, the Early Settlement Date on the Notes accepted for purchase.

In connection with the Tender Offer and Consent Solicitation, the Company is expected to consummate an offering of $2.0 billion aggregate principal amount of senior secured notes (the “Financing Transaction”), consisting of $1.0 billion in aggregate principal amount of 7.500% Senior Secured Second Lien Notes due 2031 and $1.0 billion in aggregate principal amount of 7.875% Senior Secured Second Lien Notes due 2034 on or about June 16, 2026. The Company expects to use a portion of the net proceeds from the Financing Transaction to pay the applicable consideration for all tendered Notes, plus accrued interest and all related fees and expenses.

The Company will continue to accept Notes tendered after the Early Tender Expiration. The Tender Offer and the Consent Solicitation will expire at 5:00 p.m., Central European time (11:00 a.m., New York City time), on June 30, 2026, unless extended by the Company in its sole discretion (such time and date, as the same may be extended, the “Expiration Time”). Holders of Notes who validly tender their Notes following the Early Tender Expiration and at or prior to the Expiration Time will be entitled to receive the Tender Offer Consideration. No tenders submitted after the Expiration Time will be valid. Payment for the Notes that are validly tendered at or prior to the Expiration Time and that are accepted for purchase will be made on a date promptly following the Expiration Time, which is currently anticipated to be July 6, 2026, the third business day following the Expiration Time (the “Final Settlement Date”).

The terms and conditions of the Tender Offer and the Consent Solicitation are described in an Offer to Purchase and Consent Solicitation Statement, dated June 1, 2026 (the “Offer to Purchase and Consent Solicitation Statement”). The Tender Offer and Consent Solicitation are subject to the satisfaction or waiver of certain conditions set forth in the Offer to Purchase and Consent Solicitation Statement.

The Company reserves the right to terminate or extend the Tender Offer or the Consent Solicitation if any condition to the Tender Offer or the Consent Solicitation is not satisfied (or otherwise in its sole discretion), and to amend the Tender Offer or the Consent Solicitation in any respect.

Citigroup Global Markets Inc. is the dealer manager and solicitation agent (the “Dealer Manager”) in the Tender Offer and the Consent Solicitation. Global Bondholder Services Corporation has been retained to serve as the tender and information agent (the “Tender and Information Agent”) for the Tender Offer and the Consent Solicitation. Questions regarding the Tender Offer and the Consent Solicitation should be directed to Citigroup Global Markets Inc. by telephone at +1 (212) 723-6106 (call collect) or +1 (800) 558-3745 (toll-free). Requests for copies of the Offer to Purchase and Consent Solicitation Statement and other related materials should be directed to Global Bondholder Services Corporation by telephone at (212) 430-3774 (bankers and brokers, call collect) or (855) 654-2014 (all other, toll-free); or by email at contact@gbsc-usa.com.

None of the Company, its board of directors, the Dealer Manager, the Tender and Information Agent, the trustee under the Indenture, or any of their respective affiliates, makes any recommendation as to whether any Holder should tender or deliver, or refrain from tendering or delivering, any or all of such Holder’s Notes, and none of the Company nor any of its affiliates has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amounts of Notes to tender. If any Holder is in any doubt as to the contents of this release, or the Offer to Purchase and Consent Solicitation Statement, or the action it should take, the Holder should seek its own financial and legal advice, including in respect of any tax consequences, immediately from its stockbroker, bank manager, solicitor, accountant, or other independent financial, tax, or legal adviser. The Tender Offer and the Consent Solicitation are made only by the Offer to Purchase and Consent Solicitation Statement. Holders are urged to read the Offer to Purchase and Consent Solicitation Statement carefully before making any decision with respect to the Tender Offer or the Consent Solicitation. The Offer to Purchase and Consent Solicitation Statement contains important information that should be read carefully before any decision is made with respect to the Tender Offer or the Consent Solicitation. This release does not describe all the material terms of the Tender Offer or the Consent Solicitation, and no decision should be made by any Holder on the basis of this release. The terms and conditions of the Tender Offer are described in the Offer to Purchase and Consent Solicitation Statement, and this release must be read in conjunction with the Offer to Purchase and Consent Solicitation Statement. The Tender Offer and the Consent Solicitation are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction where the securities, blue sky or other laws require the Tender Offer and the Consent Solicitation to be made by a licensed broker or dealer, the Tender Offer and the Consent Solicitation will be deemed to be made on behalf of the Company by the Dealer Manager or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction. Any individual or entity whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company, or other nominee must contact such entity if it wishes to tender such Notes pursuant to the Tender Offer.

This release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor does it constitute an offer, solicitation or sale of these securities, in any jurisdiction in which such offer, solicitation or sale is unlawful.

ABOUT WHIRLPOOL CORPORATION

Whirlpool Corporation (NYSE: WHR) is a leading home appliance company, in constant pursuit of improving life at home. As the only major U.S.-based manufacturer of kitchen and laundry appliances, the company is driving meaningful innovation to meet the evolving needs of consumers through its iconic brand portfolio, including Whirlpool, KitchenAid, JennAir, Maytag, Amana, Brastemp, Consul, and InSinkErator. In 2025, the company reported approximately $16 billion in annual net sales—close to 90% of which were in the Americas—41,000 employees and 35 manufacturing and technology research centers.

WEBSITE DISCLOSURE

We routinely post important information for investors on our website, WhirlpoolCorp.com, in the “Investors” section. We also intend to update the “Hot Topics Q&A” portion of this webpage as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors” section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our webpage is not incorporated by reference into, and is not a part of, this document.

WHIRLPOOL ADDITIONAL INFORMATION

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. Certain statements contained in this document do not relate strictly to historical or current facts and may contain forward-looking statements that reflect our current views with respect to future events and financial performance. As such, they are considered “forward-looking statements” which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “may,” “could,” “will,” “should,” “possible,” “plan,” “predict,” “forecast,” “potential,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “believe,” “may impact,” “on track,” “guarantee,” “seek,” and the negative of these words and words and terms of similar substance. Examples of forward-looking statements include, but are not limited to, statements relating to the expected timing and terms of the Tender Offer, our ability to complete the Tender Offer and, with respect to the 2027 Notes, the Consent Solicitation on the anticipated timeline or at all, as well as any other statement that does not directly relate to any historical or current fact. These forward-looking statements should be considered with the understanding that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by inaccurate assumptions. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially.

Many risks, contingencies and uncertainties could cause actual results to differ materially from Whirlpool’s forward-looking statements. Among these factors are: (1) intense competition in the home appliance industry, and the impact of the changing retail environment, including direct-to-consumer sales; (2) Whirlpool’s ability to maintain or increase sales to significant trade customers and builders; (3) Whirlpool’s ability to maintain its reputation and brand image; (4) Whirlpool’s ability to achieve its business objectives and successfully manage its strategic portfolio transformation and outsourced business unit service model; (5) Whirlpool’s ability to understand consumer preferences and successfully develop new products; (6) Whirlpool’s ability to obtain and protect intellectual property rights; (7) acquisition, divestiture, and investment-related risks, including risks associated with our past transactions; (8) the ability of suppliers of critical parts, components and manufacturing equipment to deliver sufficient quantities to Whirlpool in a timely and cost-effective manner; (9) risks related to Whirlpool’s international operations; (10) Whirlpool’s ability to respond to unanticipated social, political and/or economic events, including epidemics/pandemics; (11)  information technology system and cloud failures, data security breaches, data privacy compliance, network disruptions, and cybersecurity attacks; (12) product liability and product recall costs; (13) Whirlpool’s ability to attract, develop and retain executives and other qualified employees; (14) the impact of labor relations; (15) fluctuations in the cost of key materials (including steel, resins, and base metals) and components and the ability of Whirlpool to offset cost increases; (16) Whirlpool’s ability to manage foreign currency fluctuations; (17) impacts from goodwill, intangible asset and/or inventory impairment charges; (18) health care cost trends, regulatory changes and variations between results and estimates that could increase future funding obligations for pension and postretirement benefit plans; (19) impacts from credit rating agency downgrades; (20) litigation, tax, and legal compliance risk and costs; (21) the effects and costs of governmental investigations or related actions by third parties; (22) changes in the legal and regulatory environment including environmental, health and safety regulations, data privacy, taxes and AI; (23) the impacts of changes in foreign trade policies, including tariffs; (24) Whirlpool’s ability to respond to the impact of climate change and climate change or other environmental regulation; (25) the uncertain global economy and changes in economic conditions; (26) financing and liquidity uncertainty including payment of dividends on our 8.50% Mandatory Convertible Preferred Stock; (27) the dilutive effect of conversion and potential dividend payments in common stock for our 8.50% Mandatory Convertible Preferred Stock; (28) the liquidation preference of our 8.50% Mandatory Convertible Preferred Stock above our common stock; and (29) reduced operational flexibility and liquidity under our ABL Credit Facility. Except as required by law, we undertake no obligation to update any forward-looking statement, and investors are advised to review disclosures in our filings with the SEC. It is not possible to foresee or identify all factors that could cause actual results to differ from expected or historic results. Therefore, investors should not consider the foregoing factors to be an exhaustive statement of all risks, uncertainties, or factors that could potentially cause actual results to differ from forward-looking statements. Additional information concerning these factors can be found in our periodic filings with the SEC, including our most recent Annual Report on Form 10-K, as updated by our quarterly reports on Form 10-Q, current reports on Form 8-K and other filings we make with the SEC.

European Economic Area

Neither this Tender Offer, the Consent Solicitation, nor any other transaction set forth in the Offer to Purchase and Consent Solicitation Statement constitutes a non-exempt offer of securities to the public within the meaning of the EU Prospectus Regulation and the Tender Offer and Consent Solicitation are not subject to the obligation to publish a prospectus under the EU Prospectus Regulation. The Offer to Purchase and Consent Solicitation Statement is not a prospectus for the purposes of the EU Prospectus Regulation.

General

None of the Offer to Purchase and Consent Solicitation Statement, this announcement or the electronic transmission thereof constitutes an offer to buy or the solicitation of an offer to sell Notes (and tenders of Notes for purchase pursuant to the Tender Offer will not be accepted from Holders) in any circumstances in which such offer or solicitation is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Tender Offer or Consent Solicitation to be made by a licensed broker or dealer and a dealer manager or any of its respective affiliates is such a licensed broker or dealer in any such jurisdiction, the Tender Offer or Consent Solicitation shall be deemed to be made by the respective dealer manager or such affiliates, as the case may be, on behalf of the Company in such jurisdiction. Neither the Tender Offer, the Consent Solicitation nor our website may be used for, or in connection with, any invitation to anyone in any jurisdiction or under any circumstances in which such invitation is not authorized or is unlawful.

View original content to download multimedia:https://www.prnewswire.com/news-releases/whirlpool-announces-pricing-of-cash-tender-offer-302800692.html

SOURCE Whirlpool Corporation

Continue Reading

Technology

SQAIRZ Launches SQAIRZ Medical

Published

on

By

New Division Introduces the First Integrated Balance & Stability Platform to Help Combat Fall Risk and Support Lifelong Movement, Vitality and Independence

WINDHAM, N.H., Sept. 10, 2026 /PRNewswire/ — SQAIRZ, the biomechanically driven performance footwear company built on the belief that performance starts where you stand, today announced the launch of SQAIRZ Medical, extending the company’s expertise in stability and human movement into one of the most significant health challenges facing an aging population: fall risk and the loss of mobility, vitality and independence that can follow.

At the center of the new division is SENTRX™ purpose-built Balance & Stability footwear engineered from the ground up by SQAIRZ to help create a more stable foundation for everyday movement. In addition, SQAIRZ Medical has developed a holistic clinical framework designed to provide a critical continuum of support.

That framework integrates a Balance & Stability Protocol that connects objective fall-risk assessment, SQAIRZ’s biomechanically engineered footwear, individualized clinical intervention, and ongoing outcomes tracking into a single approach that optimizes support at every stage of the balance and stability journey.

The need is urgent. One in four U.S. adults over age 65 falls at least once every year. For adults over 80, the risk increases to one in two. Fall-related injuries account for more than $80 billion in annual U.S. healthcare spending, while also diminishing an individual’s ability to fully engage in the relationships and experiences that define quality of life.

“For more than a decade, SQAIRZ has studied the relationship between the ground, the foot, stability and human performance,” said Bob Winskowicz, Founder and CEO of SQAIRZ. “SQAIRZ Medical represents the next evolution of that work. We believe that better stability should not only help an athlete perform better. It can help people continue living better. Our goal is to identify risk earlier, provide meaningful intervention and help people maintain the movement, confidence and independence that make a full life possible.”

Beyond the Shoe: A Complete Solution

The SQAIRZ Medical approach begins with a simple premise: you cannot effectively address a risk you have not first measured.

Through the SQAIRZ Balance & Stability Program, healthcare providers can use Kinetisense® Risk of Fall and Gait Assessment technology to perform a rapid 3D movement assessment that evaluates walking speed, stride pattern, body sway, compensatory movement and an individual’s fall-risk percentage.

Those insights help inform an individualized stability plan. The SQAIRZ clinical pathway is designed around escalating levels of intervention based on identified risk, ranging from neuromuscular education and baseline guidance for lower-risk patients to appropriate orthopedic solutions.

That includes SENTRX, purpose-built balance and stability footwear engineered with a wider natural base of support, a toe box that allows the toes to spread naturally for better balance, and a high-traction outsole that helps maintain connection with the ground; and, where appropriate, Thrive Orthopedics lateral or anterior AFO bracing. Follow-up testing and outcomes tracking allow providers to reassess patients over time.

Integrates into Clinical Care

SQAIRZ Medical is being developed around the realities of clinical adoption, patient access and reimbursement.

For patients whose assessment indicates a greater need for stabilization, the SQAIRZ clinical pathway incorporates Thrive Orthopedics AFO solutions, including pathways identified in SQAIRZ materials under L1952 and L1933. The broader program is supported with provider education, treatment-pathway guidance, documentation tools, chart-note templates and letters of medical necessity.

SQAIRZ patient materials indicate that SENTRX footwear may be covered through Medicare, depending on patient qualification and coverage. Patients may also have HSA/FSA payment options.

The goal is to create a Balance & Stability solution that can live not only in consumer commerce, but inside real patient-provider workflows.

Built with Medical Expertise

The development of SQAIRZ Medical is supported by a multidisciplinary Medical Advisory Board spanning orthopedics, podiatry, physical therapy, biomechanics, sports medicine and movement science.

The advisory group includes physicians, surgeons, podiatrists, physical therapists, researchers and biomechanics experts with experience across leading medical institutions, professional sports and clinical practice. Their role extends beyond product endorsement, helping inform clinical protocols, research priorities, provider education and the continued development of evidence-based approaches to balance and stability.

“In podiatry and sports medicine, we see every day how much the relationship between the foot and the ground influences balance, confidence and movement,” said Dr. Paul Klutts, DPM, Director of Fellowship for Kentucky and Indiana Foot and Ankle. “What is compelling about SQAIRZ Medical is that it approaches stability as a system: measure risk, create a stronger foundation at the foot and connect that intervention to ongoing clinical care. SENTRX is designed to make that foundation part of everyday life.”

“Fall risk is not a single-variable problem, and it should not be addressed with a single-variable solution,” said Dr. Larry Benz, PT, DPT, OCS, MBA, MAPP, FAPTA, Founder and CEO of Confluent Health. “The opportunity with SQAIRZ Medical is to connect objective assessment, footwear, individualized intervention and outcomes tracking in a way that can fit within the continuum of care. That kind of integrated approach can help clinicians move from reacting to falls toward identifying and addressing risk earlier.”

From Performance Footwear to Performance throughout Life

SQAIRZ Medical represents a natural expansion of the company’s original mission.

SQAIRZ was founded on the belief that performance starts where you stand. Across golf, baseball, softball and pickleball, the company has focused on the relationship between the ground, the foot, stability and human movement. SQAIRZ Medical applies that same foundational thinking to a different stage of life.

“People don’t wake up wanting a stability shoe. They want to keep doing the things they love. They want another walk with their spouse, another vacation, another birthday, another afternoon with their grandchildren. They want to remain active, vital and independent for as long as possible,” Winskowicz said. “That is what we mean by SQAIRZ FOR LIFE. From helping an athlete perform to helping someone maintain their movement and independence as they age, we want SQAIRZ to be The Foundation of Human Movement throughout every stage of life.”

About SQAIRZ

SQAIRZ is a biomechanically driven performance footwear company founded on the principle that performance starts where you stand. Through footwear engineered to enhance stability, ground connection and movement, SQAIRZ serves athletes across golf, baseball, softball, pickleball and now consumers through SQAIRZ Medical. For more information, visit SQAIRZ.com or SQAIRZMedical.com.

View original content:https://www.prnewswire.com/news-releases/sqairz-launches-sqairz-medical-302874411.html

SOURCE SQAIRZ

Continue Reading

Technology

MHK and MCG Partner to Connect Evidence-Based Clinical Guidance with Standards-Based Prior Authorization

Published

on

By

New integration to help health plans streamline prior authorization and prepare for CMS-0057-F compliance

SEATTLE, Sept. 10, 2026 /PRNewswire/ — MCG Health, part of the Hearst Health network and the industry’s source of truth for trusted clinical guidance, announces a newly certified integration with MHK, a leading healthcare technology provider and a sibling Hearst Health company. The new integration connects the MCG Path interoperability solution directly with the MHK CareProminence prior authorization workflow, helping health plans streamline authorization processes while supporting standards-based interoperability required by the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F).

The prior authorization process has historically required healthcare providers and health plans to navigate separate clinical, documentation, and administrative requirements. When required clinical information is not clearly identified at the point of request, submissions may be incomplete, resulting in requests for additional information, manual follow-up, longer review cycles, and ultimately, delayed care for members. Simultaneously, health plans seek to balance adapting their current utilization management workflows to the evolution of standards-based interoperability.

The new MHK CareProminence and MCG Path integration brings highly trusted clinical guidance and documentation requirements directly into the authorization workflow, connecting capabilities that have traditionally operated as separate steps. Using HL7® Da Vinci Project burden reduction standards – including Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) – the integration surfaces evidence-based MCG clinical indications and structured documentation requirements at the point of a prior authorization request.

The integration is designed to help health plans:

Support evidence-based decision-making by incorporating the nationally recognized MCG care guidelines into the prior authorization workflowReduce administrative burden by helping providers identify and submit required clinical documentation earlier in the processPromote more consistent reviews by making structured clinical requirements available within existing workflowsAdvance interoperability readiness by supporting HL7 Da Vinci standards associated with CMS-0057-F API requirements that are primarily due January 1, 2027

One of the first to utilize the MHK-MCG integration will be Mountain Pacific, a multi-state nonprofit organization with a long history of innovation and healthcare quality improvement.

“We’re excited to integrate MHK CareProminence and MCG into our medical necessity review process for prior authorization as part of our continued commitment to modernizing healthcare delivery,” said Jill Alessi, Chief Executive Officer at Mountain Pacific. “By connecting trusted, nationally recognized, evidence-based clinical guidelines with clearer documentation requirements, this integration has the potential to reduce administrative burden, streamline the review process, facilitate timely care, strengthen collaboration, and support a more efficient experience for providers and their patients.”

“Prior authorization works best when clinical guidance, documentation requirements, and the authorization workflow are connected rather than operating as separate steps,” said Carol Helton, COO of MHK. “Bringing MCG’s trusted clinical guidance directly into CareProminence enables health plans to simplify that process while giving providers clearer information at the point of request. Equally important, this integration gives our customers a practical path toward the standards-based interoperability required under CMS-0057-F.”

“We’re seeing tremendous momentum for MCG Path as health plans across the country prepare for the next era of interoperable prior authorization,” said Jon Shreve, President and CEO of MCG Health. “Our partnership with MHK is a critical part of that progress, bringing the trust of MCG directly into the workflows health plans already use. Together, we’re driving more confident decisions that help patients get the right care.”

The certified MHK-MCG interoperability integration is currently available to health plans, and demonstrations can be requested via the MHK and MCG websites at mhk.com/contact/schedule-a-demo/ or mcg.com/contact-us/schedule-a-demo/.

About MCG Health

MCG, part of the Hearst Health network, is the trusted source of truth for clinical guidance in the healthcare industry. MCG combines evidence-based guidelines and analytics with artificial intelligence to guide efficient and accurate clinical decisions. MCG solutions are licensed by a vast majority of health plans, thousands of hospitals, and many state and federal government agencies to drive quality health outcomes while controlling costs. For more information, visit mcg.com.

About MHK

MHK, formerly MedHOK, is a leading provider of healthcare SaaS solutions for health plans, pharmacy benefit managers, and provider-sponsored organizations. MHK’s platforms support utilization management, case management, population health, pharmacy management, enrollment, and compliance. Headquartered in Tampa, Fla., MHK partners with payers nationwide to optimize operations, improve outcomes, and deliver superior member experiences. For more information, visit mhk.com.

About Mountain Pacific

Established in 1973, Mountain Pacific has decades of experience collaborating with healthcare professionals, consumers and communities across multiple states to deliver innovative solutions. Through federal, state and commercial funding and partnerships, Mountain Pacific brings national public health priorities to the local level to achieve better health outcomes, lower costs, greater access to high-quality care and improved patient experiences. Learn more at mountainpacific.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mhk-and-mcg-partner-to-connect-evidence-based-clinical-guidance-with-standards-based-prior-authorization-302868125.html

SOURCE MCG Health

Continue Reading

Technology

NuxGame Heads to SBC Summit Lisbon 2026 With Its Full Ecosystem and a Seat on the Compliance Stage

Published

on

By

LIMASSOL, Cyprus, Sept. 10, 2026 /PRNewswire/ — NuxGame, a B2B iGaming software provider, will take part in SBC Summit Lisbon 2026, held from Sept. 29 to Oct. 1 at the Feira Internacional de Lisboa. The team will be based at Stand A326 in Hall 1, the event’s Networking Lounge sponsored by NuxGame, where operators can sit down with senior staff from the product and commercial teams.

From Software Provider to Open Ecosystem

The timing suits where the business now stands. NuxGame began in 2018 as a software provider for operators launching their first projects, and today it runs an open ecosystem built around operator growth. Lisbon is one of the few occasions in the year when all of it can be seen in one place, by the people who would use it day to day.

What Operators Will See at Stand A326

Across the three days, the team will walk operators through the NuxGame Ecosystem in full:

An award-winning turnkey casino and sportsbook platform.

A game aggregator with 18,500+ titles from 140+ providers.

Sweepstakes-ready infrastructure.

A vetted network of partners covering CRM, payments, orchestration, and traffic.

That last part saves time. Instead of assessing vendors market by market, operators plug into partners already working in the regions they are entering, with the software underneath coming from a single provider. It is all backed by a service team whose client satisfaction has averaged 4.8 out of 5 over the past six months.

Denis Kosinsky on the Compliance Tech Stage

On Thursday, Oct. 1, NuxGame Chief Product Officer Denis Kosinsky will join the panel “Closing the Loopholes: How to Combat Bonus Abuse” on the Regulation & Compliance stage, part of the summit’s new Compliance Tech track. The session looks at how operators can recognize evolving patterns of bonus exploitation and keep promotional spend flowing to the players it was designed for.

“A bonus budget is one of the most powerful growth tools an operator has, and it works best when the money reaches genuine players. The instinct is to tighten the rules for everyone, but that’s like locking the whole building because one window doesn’t shut. Better to find the window. When you can see clearly how a promotion is actually being used, you close that one gap and leave the offer generous for everybody else.”

— Denis Kosinsky, Chief Product Officer at NuxGame

Book a Meeting in Lisbon

“Lisbon is where a lot of operators decide what their next year looks like. We wanted a space where those conversations can happen properly, with the platform, the content, and the partner network all in the room at once. Twenty minutes with the right people will tell you more than three months of comparing suppliers on paper.”

— Daniel Heywood, Chief Executive Officer at NuxGame

Operators, affiliates, and partners attending the summit can book a meeting with the NuxGame team in advance, or stop by Stand A326 in Hall 1 on any of the three days.

About NuxGame

NuxGame is a B2B iGaming company founded in 2018 that has grown from a software provider into an open ecosystem for operator growth. It combines an award-winning casino and sportsbook platform, a game aggregator with 18,500+ titles from 140+ providers, sweepstakes-ready infrastructure, and a vetted network of partners covering CRM, payments, orchestration, and traffic, supporting 100+ operators worldwide as they launch, scale, and enter new markets. In 2026, NuxGame was named Casino Platform of the Year at the iGaming News Awards. Visit https://nuxgame.com/ for more information and inquiries.

Media Contact: Yanina Kaplya, CMO at NuxGame, info@nuxgame.com

Original Source: https://nuxgame.com/blog/nuxgame-sbc-summit-lisbon-2026

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuxgame-heads-to-sbc-summit-lisbon-2026-with-its-full-ecosystem-and-a-seat-on-the-compliance-stage-302875384.html

SOURCE NuxGame

Continue Reading

Trending